{
  "openalex_id": "W2886025056",
  "doi": "https://doi.org/10.1158/1538-7445.am2018-5556",
  "title": "Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control",
  "abstract": "Abstract INTRODUCTION: Extracellular adenosine triphosphate (ATP) is efficiently hydrolyzed to adenosine by ecto-nucleotidases CD39 and CD73, which converts adenosine-monophosphate (AMP) into adenosine (ADO). ADO suppresses immune responses including those of T cells, natural killer (NK) cells, and dendritic cells (DC) through activation of A2aR and A2bR receptors. Treatment of cancer cells with platinum-based and anthracycline chemotherapy has been shown to induce immunogenic cell death (ICD), characterized by increased extracellular ATP levels, and upregulation of CD39 and CD73, leading to the enhanced generation of adenosine. METHODS: The ability of AB928 to inhibit adenosine-mediated suppression of immune cell function was assessed using human CD4 and CD8 cells. BALB/c mice were inoculated with AT-3-OVA tumors, which express the model antigen ovalbumin, and subsequently treated with chemotherapy or AB928 alone, or a combination of both. The growth rate and immune composition of the tumors were assessed (flow cytometry). RESULTS: Consistent with the ability of adenosine to suppress immune function, AB928 inhibited the ability of adenosine to suppress CD4 or CD8 T cell activation. Tumor-bearing mice that have been treated with either doxorubicin (DOX, an anthracycline) or oxaliplatin (OX) exhibit increased expression of CD39 and CD73. Established AT-3-OVA tumors treated with AB928 alone had a small but significant decrease in their growth rate; similarly, tumors treated with chemotherapy exhibited a reduction in growth rate. Consistent with the ICD hypothesis, treatment of AT-3-OVA-bearing mice with DOX or OX resulted in an increase in OVA-specific CD8 T cells in the tumor. Concurrent treatment with AB928 and chemotherapy resulted in significantly reduced tumor growth rates, when compared to chemotherapy alone. Analysis of the tumor-infiltrating cell populations showed a significant increase in OVA-specific CD8 T cells, relative to those treated with chemotherapy alone. CONCLUSIONS: Treatment of tumor-bearing mice with a combination of AB928, a dual A2aR and A2bR antagonist, and ICD-inducing chemotherapy results in increased tumor antigen-specific CD8 T cell responses and significantly reduced tumor growth. AB928 is currently undergoing clinical evaluation. Citation Format: Matt J. Walters, Dana Piovesan, Joanne Tan, Daniel DiRenzo, Fangfang Yin, Dillon Miles, Manmohan R. Leleti, Tim Park, Ferdie Soriano, Eshan Sharif, Ulrike Schindler, Jay P. Powers. Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5556.",
  "authors": [
    {
      "display_name": "Matt Walters",
      "id": "A5112267083",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Matt J. Walters"
    },
    {
      "display_name": "Dana Piovesan",
      "id": "A5039989206",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Dana Piovesan"
    },
    {
      "display_name": "Joanne B.L. Tan",
      "id": "A5042586940",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Joanne Tan"
    },
    {
      "display_name": "Daniel DiRenzo",
      "id": "A5015204240",
      "orcid": "https://orcid.org/0000-0002-2610-353X",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Daniel DiRenzo"
    },
    {
      "display_name": "F Yin",
      "id": "A5100651695",
      "orcid": "https://orcid.org/0000-0002-2025-4740",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Fangfang Yin"
    },
    {
      "display_name": "Dillon H. Miles",
      "id": "A5068808562",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Dillon Miles"
    },
    {
      "display_name": "Manmohan R. Leleti",
      "id": "A5056256989",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Manmohan R. Leleti"
    },
    {
      "display_name": "Tim Park",
      "id": "A5082525141",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Tim Park"
    },
    {
      "display_name": "Ferdie Soriano",
      "id": "A5062383800",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Ferdie Soriano"
    },
    {
      "display_name": "Eshan Sharif",
      "id": "A5038006715",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Eshan Sharif"
    },
    {
      "display_name": "Ulrike Schindler",
      "id": "A5031581019",
      "orcid": null,
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Ulrike Schindler"
    },
    {
      "display_name": "Jay P. Powers",
      "id": "A5071494723",
      "orcid": "https://orcid.org/0000-0002-0355-2551",
      "institutions": [],
      "is_corresponding": false,
      "raw_author_name": "Jay P. Powers"
    }
  ],
  "publication_year": 2018,
  "publication_date": "2018-07-01",
  "type": "article",
  "cited_by_count": 11,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S168522863",
    "display_name": "Cancer Research",
    "issn_l": "0008-5472",
    "issn": [
      "0008-5472",
      "1538-7445"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320273"
  },
  "volume": "78",
  "issue": "13_Supplement",
  "first_page": "5556",
  "last_page": "5556",
  "open_access": {
    "is_oa": false,
    "oa_status": "closed",
    "oa_url": null,
    "any_repository_has_fulltext": false
  },
  "concepts": [
    {
      "id": "C2776991684",
      "display_name": "Adenosine",
      "level": 2,
      "score": 0.81562984
    },
    {
      "id": "C8891405",
      "display_name": "Immune system",
      "level": 2,
      "score": 0.64500916
    },
    {
      "id": "C167672396",
      "display_name": "CD8",
      "level": 3,
      "score": 0.4942508
    },
    {
      "id": "C2777877232",
      "display_name": "Immunogenic cell death",
      "level": 4,
      "score": 0.477937
    },
    {
      "id": "C2776090121",
      "display_name": "T cell",
      "level": 3,
      "score": 0.4517646
    },
    {
      "id": "C502942594",
      "display_name": "Cancer research",
      "level": 1,
      "score": 0.4406545
    },
    {
      "id": "C172590197",
      "display_name": "Purinergic signalling",
      "level": 5,
      "score": 0.4347191
    },
    {
      "id": "C28406088",
      "display_name": "Extracellular",
      "level": 2,
      "score": 0.4219565
    },
    {
      "id": "C86803240",
      "display_name": "Biology",
      "level": 0,
      "score": 0.42053244
    },
    {
      "id": "C67907053",
      "display_name": "Adenosine receptor",
      "level": 4,
      "score": 0.37838283
    },
    {
      "id": "C71924100",
      "display_name": "Medicine",
      "level": 0,
      "score": 0.3620502
    },
    {
      "id": "C170493617",
      "display_name": "Receptor",
      "level": 2,
      "score": 0.32570654
    },
    {
      "id": "C203014093",
      "display_name": "Immunology",
      "level": 1,
      "score": 0.28855225
    },
    {
      "id": "C2777701055",
      "display_name": "Immunotherapy",
      "level": 3,
      "score": 0.26266134
    },
    {
      "id": "C134018914",
      "display_name": "Endocrinology",
      "level": 1,
      "score": 0.2498594
    },
    {
      "id": "C126322002",
      "display_name": "Internal medicine",
      "level": 1,
      "score": 0.23930389
    },
    {
      "id": "C95444343",
      "display_name": "Cell biology",
      "level": 1,
      "score": 0.2166385
    },
    {
      "id": "C2778938600",
      "display_name": "Agonist",
      "level": 3,
      "score": 0.06121829
    }
  ],
  "topics": [
    {
      "id": "T11193",
      "display_name": "Adenosine and Purinergic Signaling",
      "score": 0.9997
    },
    {
      "id": "T10158",
      "display_name": "Cancer Immunotherapy and Biomarkers",
      "score": 0.9806
    },
    {
      "id": "T10981",
      "display_name": "Cytomegalovirus and herpesvirus research",
      "score": 0.9644
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1158/1538-7445.am2018-5556",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T15:26:06.777392",
  "source_database": "OpenAlex"
}